Siltuximab: A Targeted Therapy for Idiopathic Multicentric Castleman Disease

Immunotherapy - United Kingdom
doi 10.2217/imt.15.95
Full Text
Abstract

Available in full text

Date
Authors
Publisher

Future Medicine Ltd

Related search

FDA Approval: Siltuximab for the Treatment of Patients With Multicentric Castleman Disease

Clinical Cancer Research
Cancer ResearchOncology
2015English

Predictors of Response to Anti-Il6 Monoclonal Antibody Therapy (Siltuximab) in Idiopathic Multicentric Castleman Disease: Secondary Analyses of Phase II Clinical Trial Data

British Journal of Haematology
Hematology
2018English

Long-Term Safety of Siltuximab in Patients With Idiopathic Multicentric Castleman Disease: A Prespecified, Open-Label, Extension Analysis of Two Trials

The Lancet Haematology
Hematology
2020English

Multicentric Castleman Disease: An Unusual Breast Lump

Journal of Clinical Oncology
Cancer ResearchMedicineOncology
2009English

Biologic Agents in the Treatment of Multicentric Castleman Disease

Turkish Thoracic Journal
PulmonaryRespiratory Medicine
2018English

Clinicopathologic Characteristics of 342 Patients With Multicentric Castleman Disease in Japan

Modern Rheumatology
MedicineRheumatology
2020English

Human Herpesvirus-8 Negative Multicentric Castleman Disease in a Patient With Human Immunodeficiency Virus Treated With Highly Active Antiretroviral Therapy and Chemotherapy

Cureus
2019English

The Potential Clinical Benefit of Tocilizumab Therapy for Patients With HHV-8-infected AIDS-related Multicentric Castleman Disease: A Case Report and Literature Review

Cureus
2020English

Complete Remission in a Patient With Human Herpes Virus-8 Negative Multicentric Castleman Disease Using CHOP Chemotherapy

Cancer Research and Treatment
Cancer ResearchOncology
2009English

Amanote Research

Note-taking for researchers

Follow Amanote

© 2024 Amaplex Software S.P.R.L. All rights reserved.

Privacy PolicyRefund Policy